Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eduardo Castillo Del Castillo

Gastroenterology Columbia, MD Medical Doctor

NPI 1275743221 CMS profile 628058

7120 Minstrel Way Ste 100, Columbia, MD 21045

Open in the dashboard

General payments

$13,859

810 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eduardo Castillo Del Castillo of Columbia, MD is reported in the CMS Open Payments database as having received $13,859 across 810 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,377 128
2024 General $2,220 126
2023 General $2,250 119
2022 General $2,574 135
2021 General $1,929 122
2020 General $1,309 84
2019 General $1,200 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eduardo Castillo Del Castillo
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Eduardo Castillo Del Castillo were reported at $2,377. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Eduardo Castillo Del Castillo Gastroenterology median Middle half National median
2019 $1,200 $417 $126–$1,100 $163
2020 $1,309 $224 $74–$624 $114
2021 $1,929 $352 $106–$1,054 $132
2022 $2,574 $448 $129–$1,270 $149
2023 $2,250 $533 $150–$1,390 $160
2024 $2,220 $605 $160–$1,606 $164
2025 $2,377 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,986 235 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,099 70 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $843 53 payments
  4. Celgene Corporation $757 65 payments
  5. Janssen Biotech, Inc. $696 35 payments
  6. Pfizer Inc. $633 40 payments
  7. QOL Medical, LLC $483 29 payments
  8. Genzyme Corporation $468 18 payments
  9. Intercept Pharmaceuticals, Inc. $451 22 payments
  10. Nestle HealthCare Nutrition Inc. $379 23 payments
  11. Other $4,064 220 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,801 807 payments
  2. Education $58 3 payments
Products named General payments · program years 2019–2025
  1. CREON $1,138 76 payments
  2. RINVOQ $1,003 59 payments
  3. LINZESS $933 58 payments
  4. ZEPOSIA $904 67 payments
  5. XIFAXAN $901 51 payments
  6. HUMIRA $869 50 payments
  7. SKYRIZI $843 47 payments
  8. STELARA $575 25 payments
  9. VELSIPITY $529 34 payments
  10. XELJANZ $460 29 payments
  11. Other $8,153 462 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

264

Median for Gastroenterology: 569

Drug cost

$15,315

Median for Gastroenterology: $104,976

Branded share of claims

41.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 65 $11,209
Cholestyramine Cholestyramine (With Sugar) Brand 23 $1,699
Pantoprazole Sodium Generic 85 $886
Omeprazole Generic 29 $489
Dicyclomine Hcl Generic 22 $396
Famotidine Generic 18 $354
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 22 $280

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$106,979

Medicare's payments for the services billed

Medicare patients

270

Average age 73

Services billed

1,467

174 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 46%
Diabetes 40%
Depression 20%
Ischemic heart disease 19%
Osteoporosis 17%
Chronic kidney disease 16%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
$273 — —
LINZESS
$221 — —
SKYRIZI
$215 — —
RINVOQ
$208 — —
XIFAXAN
$190 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

810 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record